journal article·2018-05-30

Design and Synthesis of a Biocompatible 1D Coordination Polymer as Anti-Breast Cancer Drug Carrier, 5-Fu: In Vitro and in Vivo Studies

Mahsa Rezaei, Alireza Abbasi, Rassoul Dinarvand, Mahmood Jeddi-Tehrani, Jan Janczak

ACS Applied Materials & Interfaces· Volume 10· Issue 21
Publisher page

Abstract

Designable coordination polymers with suitable chemical diversities and biocompatible structures have been proposed as a promising class of vehicles for drug delivery systems. Here, we hydrothermally synthesized a novel one-dimensional (1D) coordination polymer, [Zn(H2O)6K2(H2BTC)2(H2O)4](H2BTC)2·2H2O, where H3BTC = benzene-1,3,5-tricarboxylic acid (trimesic acid), cp.1. As the hydrogen bonds stabilized 1D chains in three dimensions, the cp.1 could be a good candidate for delivering small-molecule chemotherapeutics such as 5-fluorouracil (5-Fu). The synthesized cp.1 showed a remarkable 5-Fu loading of 66% with encapsulation efficiency of 98% and almost complete release process. The 5-Fu-loaded cp.1 displayed a time-dependent cytotoxicity effect against breast cancer cell lines MCF-7 and 4T1. The cellular uptake of cp.1 particles was investigated via confocal laser scanning microscopy using fluorescein isothiocyanate and LysoTracker Red staining. Furthermore, the in vivo antitumor impact of 5-Fu-loaded cp.1 was studied on 4T1 breast cancer BALB/c mice model. The intratumor treatment of 5-Fu-loaded cp.1 demonstrated beneficial antitumor efficacy by postponing tumor growth. These results suggest that the 5-Fu-loaded cp.1 microparticles with a great locoregional delivery can be efficient anticancer drug carriers for further clinical treatments.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Nanoplatforms for cancer theranostics · Supramolecular Chemistry and Complexes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Chemistry, College of Science, University of Tehran, Tehran 14155-6455, Iran

Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran 19615-1177, Iran

Institute of Low Temperature and Structure Research, Polish Academy of Sciences, P.O. Box 1410, Wroclaw 50-950, Poland

Funding

University of Tehran · Tehran University of Medical Sciences and Health Services

References (62)

Show source-provided references
1. Bailar J. C. · 1964 · 1 · 1
2. 10.1002/anie.20030061010.1002/anie.200300610 ↗
3. 10.1021/acsami.7b1452310.1021/acsami.7b14523 ↗
4. 10.1021/acsami.7b0156810.1021/acsami.7b01568 ↗
5. 10.1021/acsami.6b1496010.1021/acsami.6b14960 ↗
6. 10.1021/nn304469j10.1021/nn304469j ↗
7. 10.1021/ja803383k10.1021/ja803383k ↗
8. 10.1021/nn400223a10.1021/nn400223a ↗
9. 10.1039/c1cc10659g10.1039/c1cc10659g ↗
10. 10.1039/C5CC01937K10.1039/C5CC01937K ↗
11. 10.1021/acsnano.5b0437810.1021/acsnano.5b04378 ↗
12. 10.1039/C1JM13811A10.1039/C1JM13811A ↗
13. 10.1166/asl.2012.425110.1166/asl.2012.4251 ↗
14. 10.1016/j.colsurfb.2013.09.00910.1016/j.colsurfb.2013.09.009 ↗
15. 10.1002/smll.20120047210.1002/smll.201200472 ↗
16. 10.1002/smll.20090080910.1002/smll.200900809 ↗
17. 10.1016/j.addr.2015.04.00810.1016/j.addr.2015.04.008 ↗
18. 10.1016/j.jconrel.2005.08.01710.1016/j.jconrel.2005.08.017 ↗
19. 10.1021/acsami.7b0753510.1021/acsami.7b07535 ↗
20. 10.1039/c2cc31708g10.1039/c2cc31708g ↗
21. 10.1039/c003084h10.1039/c003084h ↗
22. 10.1039/c1cc11932j10.1039/c1cc11932j ↗
23. 10.1039/C7DT02697H10.1039/C7DT02697H ↗
24. 10.1039/C3TC32001D10.1039/C3TC32001D ↗
25. 10.1002/ange.20130748610.1002/ange.201307486 ↗
26. 10.1016/j.ccr.2011.01.03110.1016/j.ccr.2011.01.031 ↗
27. 10.1002/adma.20120174210.1002/adma.201201742 ↗
28. 10.1016/j.msec.2016.08.07310.1016/j.msec.2016.08.073 ↗
29. 10.1002/jso.293037020610.1002/jso.2930370206 ↗
30. 10.1002/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N10.1002/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N ↗
31. 10.1002/(SICI)1097-0347(199712)19:8<684::AID-HED6>3.0.CO;2-110.1002/(SICI)1097-0347(199712)19:8<684::AID-HED6>3.0.CO;2-1 ↗
32. 10.1038/nrc107410.1038/nrc1074 ↗
33. 10.1371/journal.pone.007492810.1371/journal.pone.0074928 ↗
34. 10.3390/molecules1310234010.3390/molecules13102340 ↗
35. 10.1021/am502286410.1021/am5022864 ↗
36. 10.1021/am509204u10.1021/am509204u ↗
37. 10.1021/am507345j10.1021/am507345j ↗
38. 10.1021/acsami.6b0977210.1021/acsami.6b09772 ↗
39. 10.1039/C4DT03377A10.1039/C4DT03377A ↗
40. 10.3109/14756366.2014.92634410.3109/14756366.2014.926344 ↗
41. 10.1021/am403992b10.1021/am403992b ↗
42. 10.1111/j.1365-2559.1991.tb00229.x10.1111/j.1365-2559.1991.tb00229.x ↗
43. 10.1021/acsami.7b0922710.1021/acsami.7b09227 ↗
44. 10.1016/j.inoche.2015.02.02310.1016/j.inoche.2015.02.023 ↗
45. 10.1038/s41598-017-00733-410.1038/s41598-017-00733-4 ↗
46. 10.1021/am900526u10.1021/am900526u ↗
47. 10.1038/srep3770510.1038/srep37705 ↗
48. 10.1021/acsami.6b1479510.1021/acsami.6b14795 ↗
49. 10.1016/j.biomaterials.2017.11.00110.1016/j.biomaterials.2017.11.001 ↗
50. 10.1016/j.aca.2016.03.05410.1016/j.aca.2016.03.054 ↗
51. 10.1016/j.msec.2014.12.03610.1016/j.msec.2014.12.036 ↗
52. 10.1016/j.jconrel.2017.03.02310.1016/j.jconrel.2017.03.023 ↗
53. 10.1080/21691401.2017.136942510.1080/21691401.2017.1369425 ↗
54. 10.1016/j.colsurfa.2015.11.02910.1016/j.colsurfa.2015.11.029 ↗
55. 10.1016/j.ijpharm.2016.11.01210.1016/j.ijpharm.2016.11.012 ↗
56. 10.1002/adfm.20150499810.1002/adfm.201504998 ↗
57. 10.1038/srep1137110.1038/srep11371 ↗
58. 10.2147/IJN.S3611110.2147/IJN.S36111 ↗
59. 10.1016/j.biomaterials.2010.06.05110.1016/j.biomaterials.2010.06.051 ↗
60. 10.1021/acs.molpharmaceut.5b0099210.1021/acs.molpharmaceut.5b00992 ↗
61. 10.1016/j.biomaterials.2013.10.03410.1016/j.biomaterials.2013.10.034 ↗
62. 10.1016/j.biopha.2017.10.00810.1016/j.biopha.2017.10.008 ↗